Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NHL907
- Development stage
- Phase 1
- Lead developer
- NeuHyll Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**NHL907** is an orally administered investigational drug being developed by NeuHyll. It is in a randomized, double-blind, placebo-controlled multiple-ascending-dose Phase 1 study in healthy adults to evaluate safety, tolerability, and pharmacokinetics. Its chemical composition, active components, molecular target, and mechanism of action have not been publicly disclosed in the available trial record.
- Other names
- NHL-907NHL907NHL 907
Beyond the preview
Go deeper on NHL907.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NHL907.